Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05948566 · ClinicalTrials.gov registry record · Phase 2
Strategy for Improving Stroke Treatment Response
A Phase 2 study of Ischemic Stroke, sponsored by Translational Sciences.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 300
- Enrollment target
- 20
- Study locations
NCT05948566: Recruiting Phase 2 study of Ischemic Stroke, sponsored by Translational Sciences.
NCT05948566 is a Phase 2 study of Ischemic Stroke that is actively recruiting participants, run by Translational Sciences. The registered enrollment target is 300 participants, below the 1,459-participant average among 66 other Ischemic Stroke trials with a reported enrollment target (79% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05948566, a Phase 2 study of Ischemic Stroke, is actively recruiting participants, sponsored by Translational Sciences.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 300 participants
- Enrollment target
- 20
- Study locations
Study Summary
SISTER is a Phase-II, prospective, randomized, placebo-controlled, blinded, dose finding trial that aims to determine the safety and preliminary efficacy of TS23, a monoclonal antibody against the alpha-2 antiplasmin (a2-AP), in acute ischemic stroke.
Primary Outcome
Any ICH visualized on the follow-up CT scan
Conditions Studied
Interventions
- BIOLOGICAL TS23
Study Locations (20)
California
- UCSD Health La Jolla - La Jolla
- Kaiser Permanente Los Angeles - Los Angeles
- Sutter Medical Center - Sacramento
- UCSD Medical Center- Hillcrest Hospital - San Diego
Arizona
- Banner University Medical Center - Phoenix
- Mayo Clinic Phoenix - Phoenix
- Banner University Medical Center - Tucson - Tucson
Connecticut
- Hartford Hospital - Hartford
- Yale New Haven Hospital - New Haven
Florida
- UF Health Shands Hospital - Gainesville
- Jackson Memorial Hospital - Miami
Kentucky
- Baptist Healthcare System, Inc. - Lexington
- University of Louisville Hospital - Louisville
Massachusetts
- Brigham and Women's Hospital - Boston
- Massachusetts General Hospital - Boston
Alabama
- University of Alabama Hospital - Birmingham
Delaware
- Christiana Hospital - Newark
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2024-03-18 |
| Est. Completion | 2027-12 |
| Phase | Phase 2 |
What NCT05948566 shows while recruiting
NCT05948566 is an interventional study that assigns participants to a tested intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, below the 1,459-participant average among 66 other Ischemic Stroke trials with a reported enrollment target (79% lower).
The record links to 1 condition, with Ischemic Stroke appearing as the primary indexed condition, and to 1 intervention - of which TS23 is the first listed.
NCT05948566 names 20 study sites across 11 states, led by California, Arizona, Connecticut.
Frequently Asked Questions
What is clinical trial NCT05948566 about?
NCT05948566 is a clinical study titled "Strategy for Improving Stroke Treatment Response". SISTER is a Phase-II, prospective, randomized, placebo-controlled, blinded, dose finding trial that aims to determine the safety and preliminary efficacy of TS23, a monoclonal antibody against the alpha-2 antiplasmin (a2-AP), in acute ischemic stroke.
What is the current status of trial NCT05948566?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 300 participants. The study started on 2024-03-18. Estimated completion is 2027-12.
What conditions does trial NCT05948566 study?
This clinical trial studies the following conditions: Ischemic Stroke.
What interventions are being tested in trial NCT05948566?
The interventions under investigation include: TS23 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05948566?
This trial is sponsored by Translational Sciences, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05948566 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Connecticut, Delaware. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ischemic Stroke
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05948566's enrollment target sits among peer trials
300 20th of 66 higher than 46 of 66 other Ischemic Stroke trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ischemic Stroke trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Adjunctive Intra-arterial Tenecteplase Following Mechanical Thrombectomy (ALLY) II Trial
RECRUITING · Phase 2
-
Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)
RECRUITING · Phase 2
-
Regulating Blood Pressure During Recovery From Intracerebral Hemorrhage and Ischemic Stroke
RECRUITING · Phase 2
-
Dietary Nitrate Supplements and Ischemic Stroke Recovery
COMPLETED · Phase 2
-
Mayo Acute Stroke Trial for Enhancing Recovery
COMPLETED · Phase 2
-
Combination Anti-Platelet and Anti-Coagulation Treatment After Lysis of Ischemic Stroke Trial (CATALIST)
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI